CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 398 enrolled
Drug / intervention
Sarizotan +1 moredrug
Likely dose
Sarizotan twice dailyAI-extracted
Key inclusion· 3
  • ✓Diagnosis of idiopathic Parkinson's disease
  • ✓Outpatient status
  • ✓Prior Parkinsonian medications allowed
Key exclusion· 7
  • ✕Pregnant or lactating (female participants)
  • ✕Concurrent participation in another clinical trial within 30 days
  • ✕Prior neurosurgical intervention for Parkinson's disease
  • ✕Relevant renal impairment

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00105521
NCT00105521Phase 3Completed
CompareCT.gov

A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia

EMD Serono·interventional·Posted Mar 16, 2005·Updated Apr 2, 2018

In Brief

A Phase 3 clinical trial evaluating Sarizotan and Placebo for Parkinson's Disease and Dyskinesia. Completed, enrolled 398 participants across 32 sites.

Detailed Summary

The purpose of this study is to test multiple doses of sarizotan to establish a dose with maximal safety and efficacy for treating treatment associated dyskinesia in Parkinson's disease participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease, Dyskinesia
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 16, 2005
Enrollment StartSep 30, 2004
Primary CompletionMar 31, 2006
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 21.3 years ago

Interventions

Sarizotandrug

Sarizotan will be administered twice daily.

Placebodrug

Placebo matching to sarizotan will be administered twice daily.